Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder

Yokoyama, Teruhiko; Kumon, Hiromi; Nagai, Atsushi

doi:10.1002/nau.20519

Cited by 61 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kim et al found that urinary NGF levels are increased in both men and women with OAB syndrome [20]. Yokoyama et al and associates evaluated urinary NGF in OAB patients and found that urinary NGF levels were elevated in neurogenic DO, spinal disease, and sensory urgency; however, urinary NGF was not found to be elevated in idiopathic DO [21]. It is rational to hypothesize that NGF produced in the urothelium and suburothelium can be secreted into the bladder lumen.…”

Section: Urinary Nerve Growth Factormentioning

confidence: 99%

Recent Investigations of Urinary Nerve Growth Factor as a Biomarker for Overactive Bladder Syndrome

Kuo

2009

Korean J Urol

View full text Add to dashboard Cite

Purpose: Overactive bladder (OAB) is a symptom syndrome and is usually diagnosed by subjective symptoms of urgency with or without urgency incontinence. However, because urgency symptoms are so subjective, it is difficult to objectively grade symptoms of urgency. Although urodynamic study can detect detrusor overactivity (DO) objectively, not all patients with OAB are found to have DO. Therefore, recent research interests have focused on urinary and image biomarkers in the assessment of OAB. Materials and Methods: Investigating articles from the literature and recent published works were reviewed. Results: The urinary nerve growth factor (NGF) level is found to increase in patients with OAB-wet, bladder outlet obstruction, mixed urinary incontinence, and urodynamic DO. NGF levels are correlated with OAB symptoms and return to normal after treatment. However, urinary NGF is not increased only in patients with OAB and DO. It also increases in patients with interstitial cystitis/painful bladder syndrome (IC/PBS) and other lower urinary tract diseases such as urinary tract stones, bacterial infection, and urothelial tumor. Thirty percent of OAB patients have a low urinary NGF level. Nevertheless, antimuscarinic or botulinum toxin treatment can decrease the urinary NGF level, and changes in the NGF level are correlated with the urgency severity scale. Conclusions: It is therefore possible to use urinary NGF levels as a biomarker for assessment of therapeutic outcome in patients with OAB. Further research on combined multiple biomarkers to differentiate OAB and IC/PBS is necessary. (Korean J Urol 2009;50:831-835)

show abstract

Section: Urinary Nerve Growth Factormentioning

confidence: 99%

Recent Investigations of Urinary Nerve Growth Factor as a Biomarker for Overactive Bladder Syndrome

Kuo

2009

Korean J Urol

View full text Add to dashboard Cite

show abstract

“…OAB symptom and interstitial cystitis/painful bladder syndrome (IC/PBS) are prevalent urologic diseases that can cause considerable morbidity (Jacobs et al, 2010). However, the term OAB does not actually identify specific causes or disease entities (Yokoyama et al, 2008). Although the use of an urgency perception scale or urgency severity score has been suggested, these instruments are based on subjective reporting by the patient who must grade the degree of urgency and may be difficult for patients to understand the term of urgency (De Wachter and Wyndaele, 2003;Nixon et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Urinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta-analysis

Yan

Zhang

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. To examine whether urinary tract nerve growth factor (uNGF) could be a biomarker for overactive bladder (OAB) symptom, we conducted a comprehensive meta-analysis of 8 case-control studies. In all the studies considered, patients with OAB symptom had a higher uNGF level compared to healthy people. In addition, patients had a significantly lower uNGF level after successful treatment. In the subgroup analysis, we found that patients with OAB-wet symptom had a higher uNGF level than patients with OABdry symptom. However, no significant difference was found between patients with OAB symptom and patients with interstitial cystitis/painful bladder syndrome (IC/PBS) symptom in uNGF/Cr levels. In conclusion, uNGF level could be a useful biomarker for the diagnosis of OAB, a possible biomarker for differentiation between OAB subtypes (wet or dry), and a predictive biomarker for a specific treatment, but it cannot be used as the urinary biomarker for the differential diagnosis of IC/PBS and OAB.

show abstract

“…Nerve growth factor is one of these stimulatory substances and is related to bladder hyperactivity. The urinary nerve growth factor levels in patients with neurogenic detrusor overactivity due to spinal cord injury, bladder outlet obstruction, and sensory urgency are significantly higher than those of subjects with normal cystometric findings [23] . Yoshimura et al [24] reported that chronic administration of nerve growth factor into the bladder or spinal cord of rats induced bladder hyperactivity.…”

Section: Discussionmentioning

confidence: 84%

Silodosin, an α<sub>1A</sub>-Adrenoceptor Antagonist, May Ameliorate Ischemia-Induced Bladder Denervation and Detrusor Dysfunction by Improving Bladder Blood Flow

Goi

Tomiyama²,

Maruyama³

et al. 2016

Pharmacology

View full text Add to dashboard Cite

Background/Aims: This study was performed to investigate the detailed mechanism underlying the effects of the selective α_1A-adrenoceptor antagonist, silodosin, on bladder function in a rat model of atherosclerosis-induced chronic bladder ischemia (CBI). Methods: The CBI model was prepared by balloon endothelial injury of the bilateral iliac arteries in male rats. Using an osmotic pump, the CBI rats received either silodosin or vehicle alone subcutaneously for 8 weeks. Rats received a 2% cholesterol diet throughout the experiment. Bladder blood flow (BBF) was measured. Immunohistochemical staining was performed to determine the nerve distribution and nerve growth factor expression in the bladder. Bladders were used for muscle strip contraction analysis. The expression levels of muscarinic M2 and M3 receptors were measured. Results: Silodosin abrogated the decrease in BBF in CBI rats. Silodosin prevented the decrease in nerve distribution and increase in nerve growth factor expression in the CBI model. Bladder contractile response was reduced in the CBI group. Silodosin ameliorated the effect on the bladder contractile response. The level of muscarinic M3 receptor mRNA present in the bladder of CBI rats was increased by silodosin. Conclusion: The results of this study suggest that silodosin ameliorates the denervation of the bladder and effects on detrusor contractile function under ischemic conditions by restoring BBF.

show abstract

Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder

Abstract: These data suggest that urinary NGF levels could serve as a basis for adjunct diagnosis of OAB.

Cited by 61 publications

References 32 publications

Recent Investigations of Urinary Nerve Growth Factor as a Biomarker for Overactive Bladder Syndrome

Recent Investigations of Urinary Nerve Growth Factor as a Biomarker for Overactive Bladder Syndrome

Urinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta-analysis

Silodosin, an α<sub>1A</sub>-Adrenoceptor Antagonist, May Ameliorate Ischemia-Induced Bladder Denervation and Detrusor Dysfunction by Improving Bladder Blood Flow

Contact Info

Product

Resources

About